

JYNNEOS IS THE ONLY FDA-APPROVED AND ACIP-RECOMMENDED MPOX VACCINE^{1,2}

PRODUCT OVERVIEW



JYNNEOS is indicated for prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection.³



JYNNEOS should be administered subcutaneously, preferably into the upper arm. A complete dosing regimen is 2 doses (0.5 mL each) given 4 weeks apart.³



Suspension for injection.
Each dose (0.5 mL) is supplied
in a single-dose vial.³

INDICATION AND USAGE

JYNNEOS is approved for the prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection.

IMPORTANT SAFETY INFORMATION

Appropriate medical treatment must be available to manage possible anaphylactic reactions following administration of JYNNEOS. Anyone who has experienced a severe allergic reaction following a previous dose of JYNNEOS or following exposure to any component of JYNNEOS may be at increased risk for severe allergic reactions.

Syncope (fainting) has been reported following vaccination with JYNNEOS. Procedures should be in place to avoid injury from fainting.

Immunocompromised persons, including those receiving immunosuppressive therapy, may have a diminished immune response to JYNNEOS.

Vaccination with JYNNEOS may not protect all recipients.

In smallpox vaccine-naïve healthy adults, the most common (>10%) solicited injection site reactions were pain (84.9%), redness (60.8%), swelling (51.6%), induration (45.4%), and itching (43.1%); the most common solicited systemic adverse reactions were muscle pain (42.8%), headache (34.8%), fatigue (30.4%), nausea (17.3%) and chills (10.4%).

In healthy adults previously vaccinated with a smallpox vaccine, the most common (>10%) solicited injection site reactions were redness (80.9%), pain (79.5%), induration (70.4%), swelling (67.2%), and itching (32.0%); the most common solicited systemic adverse reactions were fatigue (33.5%), headache (27.6%), and muscle pain (21.5%).

The frequencies of solicited local and systemic adverse reactions among adults with HIV infection and adults with atopic dermatitis were generally similar to those observed in healthy adults.

Across all studies, a causal relationship to JYNNEOS could not be excluded for 4 serious adverse events (SAEs), all non-fatal, which included Crohn's disease, sarcoidosis, extraocular muscle paresis and throat tightness.

Please see additional Important Safety Information throughout and full [Prescribing Information](https://bavariannordic.io/uploads/jynneos-pi.pdf) or visit <https://bavariannordic.io/uploads/jynneos-pi.pdf>.

PAYER COVERAGE: BILLING AND CODING INFORMATION

The tables below list commonly used codes to help assist healthcare providers (HCPs) with reimbursement of **JYNNEOS** administration. The information is for reference only and does not guarantee code appropriateness or assure coverage and reimbursement. Users should consult payers for relevant coverage, coding, and reimbursement details. HCPs are solely responsible for code selection and claim accuracy.

VACCINE PRODUCT IDENTIFICATION CODES

Type	Code	Description
NDC ^{3*}	50632-001-01	Single-dose vial
	50632-001-03 (Package)	Package of 10 single-dose vials
	50632-001-01 (Vial)	
CVX ^{4†}	206	Vaccinia, smallpox monkeypox vaccine, live attenuated, preservative free, subcutaneous injection
MXV ⁵	BN	Bavarian Nordic

DIAGNOSIS AND PROCEDURAL CODES

Type	Code	Description
CPT ^{6‡§}	90611	VACCINE PRODUCT CODE Vaccines, toxoids. Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection
	90460 (1st dose)	IMMUNIZATION ADMINISTRATION CODE First and second doses. Vaccine is administered with counseling (patients ≤18 years), excluding vaccines for COVID-19
	90461 (2nd dose)	
	90471 (1st dose)	IMMUNIZATION ADMINISTRATION CODE First and second doses. Vaccine is administered without counseling (patients >18 years), excluding vaccines for COVID-19
90472 (2nd dose)		
HCPCS ⁷	90611	VACCINE PRODUCT CODE Vaccines, toxoids. Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection
ICD-10-CM ^{8¶}	Z23	Encounter for immunization

*An FDA-assigned 10-digit NDC is converted by healthcare systems/payors to the HIPAA-standardized 11-digit NDC format by adding a leading zero to the applicable short segment. The HIPAA conversion for JYNNEOS is [50632-0001-03] and [50632-0001-02]. When submitting an insurance claim, it is generally recommended to use the NDC that is printed on the package of the medication. Please check with your insurance provider to confirm any specific requirements or preferences they may have regarding the submission of NDC information with your claim.

†CVX, also referred to as the vaccine administration code, specifies which vaccine product was used. It should be documented in combination with the MXV code.

‡The CPT vaccine product code (90611) must be documented in combination with 1 of the 4 CPT immunization administration codes (90460, 90461, 90471, 90472).

§CPT Copyright 2024 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.

¶The ICD-10-CM code for an encounter for immunization may be appropriate to document when submitting claims for JYNNEOS. The code should be linked to both CPT codes (vaccine product code and applicable immunization administration code).

IMPORTANT SAFETY INFORMATION (CONT.)

Cardiac adverse events of special interest (AESIs) considered causally related to study vaccination were reported in 0.08% of subjects who received JYNNEOS and included tachycardia, electrocardiogram T wave inversion, electrocardiogram abnormal, electrocardiogram ST segment elevation, electrocardiogram T wave abnormal, and palpitations. None of the cardiac AESIs considered causally related to study vaccination were considered serious.

To report SUSPECTED ADVERSE REACTIONS, contact Bavarian Nordic at 1-844-4BAVARIAN or the US Department of Health and Human Services by either visiting www.vaers.hhs.gov/reportevent.html or calling 1-800-822-7967.

Please see full [Prescribing Information](#) or visit <https://bavariannordic.io/uploads/jynneos-pi.pdf>.

ACIP, Advisory Committee on Immunization Practices; COVID-19, coronavirus disease 2019; CPT, Current Procedural Terminology; CVX, vaccine administered; FDA, US Food and Drug Administration; HCPCS, Healthcare Common Procedure Coding System; HIPAA, Health Insurance Portability and Accountability Act; ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification; MXV, Manufacturer of Vaccine; NDC, National Drug Code.

References

1. Centers for Disease Control and Prevention. JYNNEOS vaccine. Accessed January 10, 2024. <https://www.cdc.gov/poxvirus/mpox/interim-considerations/jynneos-vaccine.html> 2. Centers for Disease Control and Prevention. ACIP recommendations. Accessed January 10, 2024. <https://www.cdc.gov/vaccines/acip/recommendations.html> 3. JYNNEOS Prescribing Information. Bavarian Nordic; 2023 4. Centers for Disease Control and Prevention. Immunization Information System (IIS): HL7 standard code set CVX – vaccines administered. Accessed February 13, 2024. <https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvx> 5. Centers for Disease Control and Prevention. Immunization Information System (IIS): HL7 standard code set MXV – manufacturers of vaccines. Accessed February 13, 2024. <https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=mxv> 6. American Medical Association. 2024 CPT Professional Edition. Current Procedural Terminology (CPT®) Copyright 2024 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association. Chicago, IL: AMA; 2024. 7. NC Medicaid Division of Health Benefits. Monkeypox vaccine (Jynneos™) HCPCS code 90611: billing guidelines. Accessed February 14, 2024. <https://medicaid.ncdhhs.gov/blog/2022/10/07/monkeypox-vaccine-jynneos-hcpcs-code-90611-billing-guidelines> 8. ICD10Data.com. 2024 ICD-10-CM diagnosis code Z23. Accessed February 13, 2024. <https://www.icd10data.com/ICD10CM/Codes/Z00-Z99/Z20-Z29/Z23/Z23>.

© 2024 Bavarian Nordic Inc. All rights reserved. JYNNEOS® and the JYNNEOS® logo are registered trademarks of Bavarian Nordic A/S.